Morphological, Structural and Functional Neural Substrates of Quality of Life in Schizophrenia
Not Applicable
- Conditions
- Schizophrenia
- Registration Number
- NCT01295411
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Brief Summary
The aim of the investigators analysis is to identify the neural correlates of quality of life scores in schizophrenia. For this, the investigators will constitute group of patients according to their quality of life scores and the investigators will analyze their differences in patterns of brain structures and activations.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria (American Psychiatric Association(APA), 1994),
- age over 18 years,
- informed consent to participate in the studies
- French as native language
Exclusion Criteria
- diagnosis other than schizophrenia on Axis I of DSM-IV,
- decompensated organic disease and mental retardation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method to study the relationships between quality of life and the morphologic, structural and functional substrates in schizophrenia 36 months
- Secondary Outcome Measures
Name Time Method to determine whether quality of life is correlated with brain modifications using functional Magnetic Resonance Imaging 36 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What neural biomarkers correlate with quality of life in schizophrenia as identified by NCT01295411 MRI and neuropsychological studies?
How do structural and functional brain differences in schizophrenia patients impact quality of life metrics according to APHM's NCT01295411 trial?
What molecular mechanisms underlie the relationship between brain morphology and quality of life in schizophrenia as explored in NCT01295411?
Are there specific brain activation patterns predictive of treatment response in schizophrenia patients with varying quality of life scores from NCT01295411 data?
How does the APHM's NCT01295411 trial contribute to understanding neural substrates for developing targeted therapies in schizophrenia?
Trial Locations
- Locations (1)
Assistance Publique Hopitaux de Marseille
🇫🇷Marseille, France
Assistance Publique Hopitaux de Marseille🇫🇷Marseille, France